Abstract 417P
Background
Emerging evidence highlights the key role of microRNA (miR)-21 in cell-to-cell communication and tumorigenesis. Limited knowledge exists on the expression and clinical meaning of miR-21 in extracellular vesicles (EVs) of breast cancer (BC) patients. Thus, the aim of this study has been to assess EV-derived miR-21 expression in different BC subsets.
Methods
One hundred women were enrolled: 30 with early BC, 30 with metastatic BC on treatment progression, 30 cancer survivors on follow up and 10 healthy controls matched for age and BMI. EVs, isolated from serum samples, were characterized by nanoparticle tracking analyzer (NTA), scanning electron microscopy (SEM) and atomic force microscopy (AFM) to detect their concentration, size and structure. The miR-21 in EVs was evaluated by Real Time PCR. The expression of miR-21 was compared between groups by calculating the ΔΔCt statistic and the fold change, considering miR-16 as the housekeeping gene. The ΔΔCt was calculated using a linear mixed model approach with gene x group interaction as the parameter of interest, adjusting for age, BMI and menopausal status, and considering random intercept and random slope terms to account for individual variability.
Results
No differences in EVs size and concentration among the four groups were detected. Considering the early BC group, the clinical stage at diagnosis and tumor subtype did not influence miR-21 expression. Higher expression of miR-21 has been found in metastatic versus healthy controls (p= 0.029 95% CI -1.549 to -0.079), mainly in HER2+ and hormone receptor positive patients (p 0.0005 and 0.036, respectively). In particular, in HER2+ miR-21 was significantly higher in patients with active BC (early and metastatic) (p 0.002 95% CI -1,707 to -0,376) compared to control group.
Conclusions
While further investigations shall be requested, our data on serum EV suggest that miR-21 may become a promising biomarker for early diagnosis and tumor activity, mainly in HER2+ BC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Claudia Omarini.
Funding
MIUR Dipartimenti Eccellenti 2022.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
533P - First-line treatment in older patients with metastatic colorectal cancer: A large real-world study
Presenter: debora basile
Session: Poster session 15
534P - Second-line treatment in older patients with metastatic colorectal cancer: The ELECTRA study
Presenter: Alessia Cordua
Session: Poster session 15
535P - Safety and efficacy of first-line immune checkpoint inhibitors in elderly colorectal cancer patients: An Italian real-world multicenter experience
Presenter: Alessandra Boccaccino
Session: Poster session 15
536P - A randomized phase II/III trial comparing hepatectomy followed by mFOLFOX6 with hepatectomy alone for liver metastasis from colorectal cancer: Long-term results of JCOG0603
Presenter: Yukihide Kanemitsu
Session: Poster session 15
537P - Stereotactic ablative radiotherapy combined with fruquintinib and tislelizumab in metastatic colorectal cancer: Updated findings from a single-arm, prospective phase II trial (RIFLE)
Presenter: Yajiie Chen
Session: Poster session 15
538P - Combined hepatectomy with complete cytoreduction (CCS) and hyperthermic intraperitoneal chemotherapy (HIPEC) vs. HIPEC alone for metastatic colorectal cancer: A systematic review and meta-analysis
Presenter: Gabriele Lech
Session: Poster session 15
540P - Early treatment discontinuation (ETD) in dMMR/MSI-H metastastic colorectal cancer (mCRC) treated with immune checkpoint inhibitors (ICIs)
Presenter: Julien Taieb
Session: Poster session 15
541P - Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Subgroup efficacy and expanded safety analyses from CheckMate 8HW
Presenter: Thierry André
Session: Poster session 15